Federal Grant Award Summary

Amygo Solutions LLC received a $304,643 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation's Directorate for Technology, Innovation, and Partnerships (CFDA 47.084) effective July 1, 2026, through August 31, 2027. The company will develop and validate a novel blood test diagnostic for detecting transthyretin amyloidosis, a progressive protein misfolding disorder affecting approximately 500,000 individuals in the United States. The test will identify harmful protein aggregates in blood samples using a newly discovered protein-binding molecule adapted into a reliable, high-throughput format compatible with standard laboratory equipment. Key deliverables include test format design, evaluation of antibody and detector combinations, validation experiments to confirm accuracy and reproducibility, and performance assessment across diverse patient samples.

This diagnostic innovation addresses a significant clinical gap, as current diagnostic methods for transthyretin amyloidosis are costly, invasive, and frequently delayed by years, often precluding timely intervention. The proposed blood test offers a low-cost, noninvasive alternative that could reduce per-patient diagnostic costs by thousands of dollars while enabling earlier treatment and improved patient outcomes. Beyond its immediate application to cardiac amyloidosis, the underlying technology platform has potential applicability to other protein misfolding disorders including Alzheimer's and Parkinson's disease, positioning the company for broader commercial opportunity and enhanced societal impact through reduced healthcare burden.